Can you get lung cancer screening before 50? What each guideline says

This guide quotes four US rules. The USPSTF sets the federal preventive-care standard, the American Cancer Society (ACS) and the American College of Chest Physicians (CHEST) are professional guideline bodies, and the Centers for Medicare & Medicaid Services (CMS) decides what Medicare pays for. On the starting age they agree more closely than on anything else.

The National Comprehensive Cancer Network also publishes lung screening guidance. Its current guideline sits behind an account login, so we have not quoted it here.

For someone who already meets the smoking threshold, age is the only barrier. A pack a day from age 18 reaches 20 pack-years at 38 (our arithmetic: packs per day multiplied by years smoked), twelve years before any of these rules begins.

The starting age rests on the trials and on modeling. The National Lung Screening Trial, the largest trial with 53,454 participants, enrolled people aged 55 to 74. The NELSON trial enrolled people aged 50 to 74, and the USPSTF notes that about one-fourth of its participants were younger than 55. Neither enrolled anyone under 50.

The USPSTF also commissioned modeling from the Cancer Intervention and Surveillance Modeling Network. The CISNET modeling study (Meza et al., JAMA 2021) states that the strategies it tested varied by starting age (45, 50 and 55 years), so screening from 45 was examined directly. Its abstract, as published in JAMA: "Most of the efficient risk factor-based strategies started screening at aged 50 or 55 years and stopped at aged 80 years." The USPSTF puts the same finding as "Almost all have a starting age of 50 or 55 years."

Harms are the other half of that balance. The USPSTF lists them as "false-positive results leading to unnecessary tests and invasive procedures, overdiagnosis, radiation-induced cancer, incidental findings, and increases in distress or anxiety." In the National Lung Screening Trial, 26.3% of baseline scans were false positives. Radiation is one of those harms, and the USPSTF reports the trade directly: its 2021 criteria were estimated to cause 38.6 radiation-related lung cancer deaths per 100,000 people in the population aged 45 to 90, against 20.6 under the older, narrower 2013 criteria, or one death caused for every 13.0 lung cancer deaths avoided. It also notes that programs that "start at younger ages or use a lower pack-year eligibility screen a larger total number of persons."

CHEST is the only body that leaves a door open below 50, and it is a narrow one. Its fourth recommendation reads: for people who "are younger than age 50 or older than 80, or have quit smoking more than 15 years ago, and are not projected to have a high net benefit from lung cancer screening based on clinical risk prediction or life-year gained calculators, we recommend that low dose CT screening should not be performed." That is a strong recommendation against.

The exception is its third recommendation, a weak one: for people who do not meet "the smoking and/or age criteria in Recommendations #1 and 2 but are projected to have a high net benefit from lung cancer screening based on the results of validated clinical risk prediction calculations and life expectancy estimates, or based on life-year gained calculations," CHEST suggests screening should be offered. The summary version says "asymptomatic individuals"; the version in the guideline's main text says "asymptomatic smokers and former smokers."

CHEST does not say how many people under 50 clear these thresholds, and we have not estimated it. It does say two practical things. Using calculators "is more burdensome than identification using the criteria in Recommendations #1 and 2 alone." And on payment: "In the United States, health insurance providers may not pay for low-dose CT screening for those who do not meet the eligibility criteria listed in Recommendation #1 or 2." Both of those criteria start at 50 or later.

The USPSTF names the other risks plainly: "Other risk factors for lung cancer include environmental exposures, prior radiation therapy, other (noncancer) lung diseases, and family history." Some public comments on its draft raised exactly this point. Its answer: "the USPSTF acknowledges that there are risk factors for lung cancer other than smoking; however, current evidence does not support the incorporation of these risk factors as determinants of eligibility for lung cancer screening."

It also acknowledges "that lung cancer can occur in persons who never smoked," and gives its reason for keeping smoking at the center: "all trials of screening for lung cancer have been conducted among persons who smoke or were former smokers." The ACS guideline is framed the same way, as guidance for people "at high risk for lung cancer due to a history of smoking."

CHEST also cites a modeling study by National Cancer Institute researchers that asked how much three yearly low-dose CT scans would have to cut lung cancer deaths to outweigh the lung cancer deaths their radiation could cause. For scans at ages 40 to 42, the answer was 70% for women who never smoked and 10% for men who currently smoke; for scans at 50 to 52, it was 25% and 2%. Its conclusion: "Before age 50, the mortality reduction from lung CT screening that is required to outweigh the radiation risk may be substantial, and in some cases unattainable (i.e. >100%)." The study modeled never-smokers in general, not people with a family history of lung cancer, and we have not estimated what it would show for them.

Here the rules split. ACS dropped years since quitting from its criteria in 2023, and its announcement spells out the under-50 consequence: people who "have a 20+ pack-year history and reach their 15th year since quitting before age 50 will now be eligible to start and continue screening." The USPSTF and Medicare keep the 15-year limit, and CHEST keeps it in both of its bands.

Take a reader who built up 20 pack-years and quit at 33 (our application of the published criteria). At 50 they are 17 years smoke-free. Under ACS they are eligible from 50 to 80. Under the USPSTF and CHEST's two bands they are not, and Medicare would not cover the scan. Our guide to when lung cancer screening stops after quitting sets out that disagreement in full.

Every rule above is for people without symptoms. ACS is direct: "If you have symptoms that could be from lung cancer, see your doctor right away," and testing done to find their cause "is for diagnosis and is not the same as screening." CHEST asks screening programs to check for symptoms first so that symptomatic patients "receive appropriate diagnostic testing, regardless of whether the symptomatic patient meets screening eligibility criteria." Medicare's coverage requires the person to be asymptomatic. Age limits on screening say nothing about whether a symptom at 42 should be investigated.

Our lung cancer screening page carries the full eligibility rows for USPSTF, ACS and CHEST, each quoted and dated, with how the scan is done and what follows an abnormal result. Your personal screening plan lists the screenings that apply at your age and sex, and our guide to health in your 40s covers the screenings that do start in that decade.

If you are under 50 with a heavy smoking history, questions worth taking to a clinician: which body's criteria does the practice follow, would a CHEST risk calculator be used, and would my insurer pay for a scan outside the standard criteria. If your concern is family history rather than smoking, the question is how your clinician weighs it, since none of the four rules uses it. ACS puts quitting plainly: "Screening is not a good alternative to stopping smoking." For the routine numbers that sit alongside screening in these years, see the blood tests worth getting every year.